The immune response and antibacterial therapy

被引:15
作者
Anuforom, Olachi [1 ,2 ]
Wallace, Graham R. [2 ,3 ]
Piddock, Laura V. [1 ,2 ]
机构
[1] Univ Birmingham, Inst Microbiol & Infect, Antimicrobials Res Grp, Birmingham B15 2TT, W Midlands, England
[2] Univ Birmingham, Sch Immun & Infect, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England
[3] Univ Birmingham, Ctr Translat Inflammat, Birmingham B15 2TT, W Midlands, England
关键词
Antibiotics; Immune response; Bacteria; Host; Infection; Treatment; STAPHYLOCOCCUS-AUREUS; MYCOBACTERIUM-TUBERCULOSIS; TRANSPLANT RECIPIENTS; INFLAMMATORY RESPONSE; MURINE MODEL; IN-VIVO; INFECTIONS; ANTIBIOTICS; RESISTANT; EFFICACY;
D O I
10.1007/s00430-014-0355-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The host's immune defence mechanisms are indispensable factors in surviving bacterial infections. However, in many circumstances, the immune system alone is inadequate. Since the 1940s, the use of antibacterial therapy has saved millions of lives, improving the span and quality of life of individuals. Unfortunately, we are now facing an era where antibacterial agents are threatened by resistance. In addition to targeting bacteria, some antibacterial agents affect various aspects of the immune response to infection. Since many antibacterial drugs are failing in efficacy due to resistance, it has been strongly suggested that any synergy between these drugs and the immune response be exploited in the treatment of bacterial infections. This review explores the influence of antibacterial therapy on the immune response and new approaches that could exploit this interaction for the treatment of bacterial infections.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 92 条
[1]  
Algar V., 2007, Paediatrics and Child health, V17, P132, DOI [10.1016/j.paed.2007.02.001, DOI 10.1016/J.PAED.2007.02.001]
[2]  
Ampel N M, 1990, Semin Respir Infect, V5, P30
[3]   Determination of minimum inhibitory concentrations [J].
Andrews, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 :5-16
[4]   EFFECTS OF QUINOLONES ON TUMOR NECROSIS FACTOR PRODUCTION BY HUMAN-MONOCYTES [J].
BAILLY, S ;
FAY, M ;
ROCHE, Y ;
GOUGEROTPOCIDALO, MA .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1990, 12 (01) :31-36
[5]   EFFICACY OF ANTI-MICROBIAL THERAPY IN EXPERIMENTAL RAT PNEUMONIA - EFFECTS OF IMPAIRED PHAGOCYTOSIS [J].
BAKKERWOUDENBERG, IAJM ;
JONGHOENDEROP, JYTD ;
MICHEL, MF .
INFECTION AND IMMUNITY, 1979, 25 (01) :366-375
[6]  
Borody T, 2002, AM J GASTROENTEROL, V97, P3032, DOI 10.1111/j.1572-0241.2002.07121.x
[7]   Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits [J].
Brandl, Katharina ;
Plitas, George ;
Mihu, Coralia N. ;
Ubeda, Carles ;
Jia, Ting ;
Fleisher, Martin ;
Schnabl, Bernd ;
DeMatteo, Ronald P. ;
Pamer, Eric G. .
NATURE, 2008, 455 (7214) :804-U8
[8]  
BROOK I, 1991, REV INFECT DIS, V13, P1170
[9]   Differential effects of β-lactams on human IFN-γ activity [J].
Brooks, BM ;
Hart, CA ;
Coleman, JW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (06) :1122-1125
[10]   Whole-Animal Chemical Screen Identifies Colistin as a New Immunomodulator That Targets Conserved Pathways [J].
Cai, Yun ;
Cao, Xiou ;
Aballay, Alejandro .
MBIO, 2014, 5 (04)